Antidenaturant drugs for cataract and other condensation diseases

‘Condensation diseases’ are heterogeneous pathological conditions in which the primary pathogenetic step is the loss of solubility of specific substances, resulting in the formation of a condensed phase. Typical examples are cataract, nephrolithiasis, gallstone disease and certain rheumatic conditio...

Full description

Saved in:
Bibliographic Details
Published in:Medical hypotheses 2001-01, Vol.56 (1), p.114-120
Main Authors: Saso, L., Silvestrini, B.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cataract - drug therapy
Cholelithiasis - drug therapy
Crystallins - chemistry
Humans
Kidney Calculi - drug therapy
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Protein Denaturation
Rheumatic Diseases - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:‘Condensation diseases’ are heterogeneous pathological conditions in which the primary pathogenetic step is the loss of solubility of specific substances, resulting in the formation of a condensed phase. Typical examples are cataract, nephrolithiasis, gallstone disease and certain rheumatic conditions in which protein denaturation, aggregation and precipitation may occur. Since the condensing molecules are often proteins, antidenaturant agents should be considered rational drugs for the treatment of these diseases. Surprisingly, however, only a few molecules with these properties are currently available for therapeutic use, including bendazac for cataract.
ISSN:0306-9877
1532-2777
DOI:10.1054/mehy.2000.1128